N/A N=25 Changes in Cerebral Oxygenation During Laparoscopic Pyloromyotomy
Pyloric Stenosis
Primary: Cerebral Regional Oxygen Saturation (rSO2) — 81 percentage of oxygen
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=35 A Study of Lasmiditan in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan — 368; 304 Nanograms Per Millilitre (ng/mL)
Phase 2 N=68 Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
Prostate Cancer
Primary: Proportion of Participants With Pathologic Stage Less Than or Equal to ypT2N0 — 13; 11 Participants
N/A N=84 Clinical Trial to Evaluate the Symptoms in Symptomatic Contact Lens Wearers Following Application of Intranasal Tear Neurostimulator Versus Control
Dry Eye Syndromes
Primary: Contact Lens Dry Eye Questionnaire (CLDEQ-8) Score in the Study Eye — 15.3; 17.2 score on a scale — p=0.116
Phase 4 N=50 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
Venous Thromboembolism · Multiple Myeloma
Primary: Frequency of Symptomatic Venous Thromboembolism — 0 Participants
Phase 2 N=38 Spondylitis Trial of Apremilast for Better Rheumatic Therapy
Ankylosing Spondylitis
Primary: Changes of Apremilast in Patients With AS, Changes in BASDAI Score From Baseline — -0.77; -1.59 units on a scale — p=0.139
Phase 2 N=7 Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
Frontotemporal Lobar Degeneration (FTLD) · Frontotemporal Dementia (FTD) · Tauopathies
Primary: SUVR of 18F-AV-1451 — 1.07; 1.26; 1.03; 1.34 standardized uptake value ratio (SUVR)
Phase 2 N=8 Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator
Hematologic Neoplasms
Primary: Overview of Adverse Events (Safety Set) — 6; 2; 2; 3 participants
N/A N=10 Using the LENA System in Early Intervention - b
Depression
Primary: LENA Adult Word Count Score at 6 Weeks — 18391.25 number of words
Phase 1 N=12 Investigation of the Safety of Intranasal Glulisine in Down Syndrome
Down Syndrome
Primary: Safety Measured by Adverse Events — 0; 0 Participants
N/A N=1,335 Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Participants With Adverse Drug Reactions — 3.93 Percentage of participants (%)
Phase 2 N=24 Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee
Osteoarthritis of the Knee
Primary: Change From Baseline in 24-hour Weighted Mean Serum Cortisol — -7.7; -42.7; -62.2; -59.0 weighted mean serum cortisol (nmol/L)
Phase 2 N=60 Traditional Chinese Medicine in the Treatment of Patients With Hyperuricemia.
Hyperuricemia
Primary: Serum Uric Acid<6 mg/dL at Week 4 — 0; 1; 1 Participants
Phase 2 N=7 Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations
Insulin Resistance · Diabetes Mellitus · Abnormal Glucose Metabolism
Primary: Total Body Glucose Disposal in the Fasting State — 21.47 μmol/kg LBM (Lean Body Mass)/min
Phase 2 N=10 (+) Epicatechin to Treat Friedreich's Ataxia
Friedreich's Ataxia
Primary: Change From Baseline in Friedreich Ataxia Rating Scale (FARS) Composite Score — 55.0 score on a scale — p=0.336